ACEA 1021 IN PATIENTS WITH ACUTE STROKE
ACEA 1021 用于急性中风患者
基本信息
- 批准号:5218906
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
This present study of ACEA 1021 is a multi-center, double-blind,
centrally-randomized, vehicle-controlled, single-dose, rising tolerance
design to evaluate the safety, tolerability, and pharmacokinetics of ACEA
1021 in patients with acute stroke. Forty-five patients who fulfill
criteria will be treated within 48 hours of onset of stroke symptoms and
will be studied in five sequential dosing groups at three to five sites.
Each group will consist of a minimum of nine patients, of whom six will
receive the test article, ACEA 1021, and three will receive the
vehicle-control, 0.05 M Tromethamine (Tris).
Patients will be evaluated at several time points for safety and
tolerability. Each patient will be closely observed and will have
continuous monitoring of cardiac rhythm during the infusion and for 24
hours after administration is complete, and will have laboratory tests
(CBC, Chemistry, and urinalysis) at 24 hours, 48 hours, one week, and one
month post-dosing. Each patient will remain hospitalized during the
infusion and for 48 hours after administration of ACEA 1021. Each
patient will be seen as an outpatient (if discharged from hospital) at
one week and one month post-dose in order to evaluate their clinical
status. ACEA 1021 levels will be drawn at baseline, at the end of study
drug infusion, at fifteen minute intervals for the first hour post-dose,
and at 2, 4, 8, 12, 24, and 48 hours post-dose. Patients will be
followed for 30 days.
This study represents the first administration of ACEA 1021 in humans.
ACEA 1021 is a new molecular entity (5-nitro-6, 7-dichloro-2,
3-quinoxalinedione) which acts as an N-methyl-D-asparate (NMDA)
antagonist at the glycine site. It provides neuroprotection in multiple
models of cerebral ischemia, both in vitro and in vivo, as well as in
vivo models of seizure and pain. It has an approved cardiovascular and
CNS safety profile compared with other NMDA antagonists and an acceptable
toxicology profile for administration of a single dose in humans.
In the preclinical animal studies, risks attributed to ACEA 1021 included
CNS effects, liver and renal toxicity, mild anemia, and local irritation
at the infusion site. Risks of ACEA 1021 have included PCP-like side
effects, vomiting or effects on blood pressure and heart rate.
Nevertheless, these parameters will be monitored during the infusion and
for 48 hours after infusion is completed. The minimal vacuolization
without necrosis of neurons seen with acute administration of 30 mg/kg
in rats, and conflicting results in genetotoxicity studies must also be
considered in the risk assessment, but cannot be monitored during this
study.
本ACEA 1021研究是一项多中心、双盲、
中心随机化、溶剂对照、单次给药、耐受性升高
旨在评价ACEA的安全性、耐受性和药代动力学
1021例急性卒中患者。 45名患者符合
标准将在中风症状发作后48小时内治疗,
将在三至五个研究中心的五个连续给药组中进行研究。
每组将由至少9名患者组成,其中6名将
接受供试品ACEA 1021,三人将接受
溶剂对照,0.05 M氨丁三醇(Tris)。
将在几个时间点评价患者的安全性,
耐受性 每一个病人都将被密切观察,
在输注期间连续监测心律,
小时后,管理完成,并将有实验室检查
(CBC 24小时、48小时、一周和一周后的尿分析)
给药后1个月。 每名患者将继续住院期间,
输注和ACEA 1021给药后48小时。 每个
患者将被视为门诊患者(如果出院),
给药后1周和1个月,以评价其临床
status. 将在基线、研究结束时采集ACEA 1021水平
药物输注,给药后第一个小时间隔15分钟,
以及给药后2、4、8、12、24和48小时。 患者将
跟踪30天。
本研究是ACEA 1021首次用于人体。
ACEA 1021是一种新的分子实体(5-硝基-6,7-二氯-2,
3-喹喔啉二酮),其作为N-甲基-D-喹喔啉酸酯(NMDA)
在甘氨酸位点的拮抗剂。 它提供了多种神经保护,
脑缺血模型,在体外和体内,以及在
癫痫发作和疼痛的体内模型。 它具有批准的心血管和
与其他NMDA拮抗剂相比的CNS安全性特征和可接受的
在人体中单次给药的毒理学特征。
在临床前动物研究中,ACEA 1021的风险包括
CNS影响、肝脏和肾脏毒性、轻度贫血和局部刺激
在输液部位。 ACEA 1021的风险包括PCP样侧
呕吐或对血压和心率的影响。
然而,将在输注期间监测这些参数,
输注完成后48小时。 最小空泡化
30 mg/kg急性给药未观察到神经元坏死
遗传毒性研究中相互矛盾的结果也必须
在风险评估中考虑,但在此期间无法监测
study.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GREGORY W ALBERS其他文献
GREGORY W ALBERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GREGORY W ALBERS', 18)}}的其他基金
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials Network
斯坦福大学 NIH 卒中试验网络区域卒中协调中心
- 批准号:
10851445 - 财政年份:2023
- 资助金额:
-- - 项目类别:
PRECISE (PeRfusion imaging to identify postErior CIrculation candidateS for thrombectomy)
PRECISE(灌注成像以识别血栓切除术的后循环候选者)
- 批准号:
10186074 - 财政年份:2021
- 资助金额:
-- - 项目类别:
PRECISE (PeRfusion imaging to identify postErior CIrculation candidateS for thrombectomy)
PRECISE(灌注成像以识别血栓切除术的后循环候选者)
- 批准号:
10453667 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials Network
斯坦福大学 NIH 卒中试验网络区域卒中协调中心
- 批准号:
9755525 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials Network
斯坦福大学 NIH 卒中试验网络区域卒中协调中心
- 批准号:
10467057 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NIH Stroke Trials Network
斯坦福大学 NIH 卒中试验网络区域卒中协调中心
- 批准号:
10306022 - 财政年份:2018
- 资助金额:
-- - 项目类别:
DEFUSE 3: EnDovascular ThErapy Following Imaging EvalUation for ISchemic StrokE 3
DEFUSE 3:缺血性中风影像评估后的血管内治疗 3
- 批准号:
9146680 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NINDS Stroke Tria
斯坦福大学 NINDS 卒中试验区域卒中协调中心
- 批准号:
8895434 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NINDS Stroke Tria
斯坦福大学 NINDS 卒中试验区域卒中协调中心
- 批准号:
8662402 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Stanford University Regional Coordinating Stroke Center for the NINDS Stroke Tria
斯坦福大学 NINDS 卒中试验区域卒中协调中心
- 批准号:
9118342 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
-- - 项目类别: